Somatic Gene Changes Associated with Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

被引：0
|
作者：
Pachimatla, A. G. [1 ]
Kalvapudi, S. [1 ]
Bawek, S. [2 ]
Vedire, Y. [1 ]
Jain, P. [1 ]
Yendamuri, S. [1 ]
Patnaik, S. [1 ]
机构：
[1] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[2] Univ Buffalo, Buffalo, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
immunotherapy response; gene mutations; KRAS and TP53;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.11A.06
引用
收藏
页码：S597 / S598
页数：2
相关论文
共 50 条
  • [21] Safety of current immune checkpoint inhibitors in non-small cell lung cancer
    Abdayem, Pamela
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 651 - 667
  • [22] Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
    Wang, Shuai
    Hao, Jiatao
    Wang, Hao
    Fang, Yong
    Tan, Lijie
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [23] Immune checkpoint inhibitors in therapy of non-small cell lung cancer (a review)
    Kolesnik, O. P.
    Mykhailychenko, V. V.
    ZAPOROZHYE MEDICAL JOURNAL, 2021, 23 (03) : 418 - 425
  • [24] Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
    Zhenbin Qiu
    Zihao Chen
    Chao Zhang
    Wenzhao Zhong
    Experimental Hematology & Oncology, 8
  • [25] Identification of gene signatures relevant to the efficacy of immune checkpoint inhibitors in non-small cell lung cancer
    Liu, Min
    Li, Qiao
    Meng, Xiaohong
    Cui, Yanan
    Sun, Weirong
    Wang, Hongmei
    Gao, Qingjun
    MEDICINE, 2024, 103 (49)
  • [26] Obesity, dyslipidemia, and diabetes as determinants of response to immune checkpoint inhibitors in non-small cell lung cancer
    Osataphan, Soravis Alm
    Awidi, Muhammad
    Jan, Yu Jen
    Sundararaman, Shriram
    Viray, Hollis
    Frankenberger, Edward
    Mariano, Melissa
    Stafford, Katherine Ann
    Kolnick, Aleksandra
    Ghazalah, Hind
    Patti, Mary-Elizabeth
    Gunturu, Krishna Soujanya
    Rangachari, Deepa
    Costa, Daniel Botelho
    Lam, Prudence B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
    Nicos, Marcin
    Krawczyk, Pawel
    Crosetto, Nicola
    Milanowski, Janusz
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [28] Sex differences in tolerability and response to immune checkpoint inhibitors in non-small cell lung cancer patients
    Duma, Narjust
    Azzouqa, Abdel-Ghani
    Yadav, Siddhartha
    Hoversten, Kahterine
    Reed, Clay
    Sitek, Andrea
    Enninga, Elizabeth
    Paludo, Jonas
    Kottschade, Lisa
    Mansfield, Aaron
    Manochakian, Rami
    Dronca, Roxana
    Adjei, Alex
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [29] Identification of immune-related gene signature for non-small cell lung cancer patients with immune checkpoint inhibitors
    Wang, Li
    Han, Chaonan
    Cai, Chenlei
    Wu, Jing
    Chen, Jianing
    Su, Chunxia
    HELIYON, 2024, 10 (05)
  • [30] Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases
    Wei Yuxi
    Xu Yan
    Wang Mengzhao
    中华医学杂志英文版, 2023, 136 (13)
12345